10 Papers
1 Citations
Peng Lu is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
Marc A. Riedl,Marcus Maurer,Jonathan A. Bernstein,Aleena Banerji,Hilary Longhurst,H. Henry Li,Peng Lu,James Hao,Salome Juethner,William R. Lumry,Help Study Investigators +10 more
TL;DR: Lanadelumab demonstrated efficacy in preventing hereditary angioedema attacks in the phase 3 HELP Study, and was approved for use in girls with atypical HAEs.
Association of complement components with the risk and severity of NAFLD: A systematic review and meta-analysis
Jianbo Zhao,Yafei Wu,Peng Lu,Xiaoqin Wu,Junming Han,Yingzhou Shi,Yue Liu,Yiping Cheng,Ling Gao,Jiajun Zhao,Zhen Wang,Xiude Fan +11 more
TL;DR: Wang et al. as discussed by the authors conducted a meta-analysis to evaluate the association of complement components with the risk and severity of NAFLD. But the relationship between complement components and the risk of nonalcoholic fatty liver disease (NAFLD) is inconsistent.
Crohn’s disease patients with L4-esophagogastroduodenal phenotype is associated with a better prognosis: A retrospective cohort study
Jing-rong Weng,Xutao Lin,Xi Chen,Yufan Liang,Yujun Xu,Jiawei Cai,Peng Lu,Yuming Rong,Yifeng Zou,Lixin Zhu +9 more
TL;DR: In this paper , the authors investigated whether the prognosis differs between L4 Crohn's disease patients with and without esophagogastroduodenal involvement and non-L4-EGD patients by using multivariable logistic regression analysis.
Development of phvs719: an oral extended-release bradykinin b2 receptor antagonist to prevent hereditary angioedema attacks
TL;DR: In this paper , the authors developed a PHA121 formulation (PHVS719) providing 24-hour plasma exposure, which relied upon a combination of an optimally designed extended-release formulation and the ability of PHA-121 to be absorbed throughout the full gastrointestinal tract.
1
Pharmacokinetics of phvs719, extended-release tablet formulation of pha121, a first-in-class oral human bradykinin b2-receptor antagonist
K. Groen,Raf Crabbé,Julienne Knolle,C. Gibson,Anne Lesage,Peng Lu +5 more
TL;DR: In this article , a single dose of PHVS719 yielded exposure of PHA121 above EC 85 by 3-hour timepoint and maintained it for at least 28 hours with or without food.
1